Dermata Therapeutics, Inc. (DRMA) Form 424B3 — May 29, 2026
Dermata Therapeutics, Inc. filed a prospectus supplement (424B3) registering up to $100 million in common stock, preferred stock, warrants, debt securities, subscription rights, and units on a shelf basis. This filing enables the company to offer these securities from time to time in one or more offerings, with specific terms to be determined by market conditions at the time of each sale. The company disclosed a public float of approximately $3.96 million based on 3.19 million shares held by non-affiliates at $1.24 per share.
Key figures
- Last Sale Price
- 1.24
- Shelf Capacity
- 100000000
- Public Float Shares
- 3189661
- Shares Outstanding
- 4022143
- Atm Fees Jan2026
- 67000
- Atm Proceeds Jan2026
- 2000000
- Warrant Exercise Price
- 16800
- Warrant Expiration Date
- 2026-08-17
AI analysis
Red flags5 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.